Tissue microarray - a high-throughput molecular analysis in head and neck cancer.

With the identification of a number of novel markers having diagnostic, prognostic, and therapeutic significance, the application of tissue microarray (TMA) has become a valuable tool for validating candidate markers in cancer research. The TMA is a high-throughput technique, which allows large-scale analyses of hundreds of archival clinical tissue samples using the 'array' approach. This paper highlights briefly its robust technology, technical aspects of its construction, and the validity of the TMA results for oral pathology diagnostics by reviewing data from recent literature particularly with reference to head and neck cancer.

[1]  Robert Camp,et al.  Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[2]  P. Lichter,et al.  High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy , 2007, International journal of cancer.

[3]  M. Rasse,et al.  High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. , 2007, Oral oncology.

[4]  F. Bosch,et al.  Comparison of p16INK4a expression with p53 alterations in head and neck cancer by tissue microarray analysis , 2007, The Journal of pathology.

[5]  S. Merajver,et al.  RhoC GTPase Expression as a Potential Marker of Lymph Node Metastasis in Squamous Cell Carcinomas of the Head and Neck , 2006, Clinical Cancer Research.

[6]  T. Chou,et al.  Increased NBS1 Expression Is a Marker of Aggressive Head and Neck Cancer and Overexpression of NBS1 Contributes to Transformation , 2006, Clinical Cancer Research.

[7]  U. Joos,et al.  Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity , 2006, BMC Cancer.

[8]  U. Joos,et al.  Catenin expression in T1/2 carcinomas of the floor of the mouth. , 2005, International journal of oral and maxillofacial surgery.

[9]  P. Lichter,et al.  Amplification of Cyclin L1 is associated with lymph node metastases in head and neck squamous cell carcinoma (HNSCC) , 2005, British Journal of Cancer.

[10]  Xueli Liu,et al.  Statistical Methods for Analyzing Tissue Microarray Data , 2004, Journal of biopharmaceutical statistics.

[11]  Cecelia E Schmalbach,et al.  Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma , 2004, Cancer.

[12]  M. Rodriguez-Pinilla,et al.  Cyclin A as a Predictive Factor for Chemotherapy Response in Advanced Head and Neck Cancer , 2004, Clinical Cancer Research.

[13]  D. Rimm,et al.  Prognostic Significance of p16 Protein Levels in Oropharyngeal Squamous Cell Cancer , 2004, Clinical Cancer Research.

[14]  Holger Moch,et al.  Impaired Expression of the Cell Cycle Regulator BTG2 Is Common in Clear Cell Renal Cell Carcinoma , 2004, Cancer Research.

[15]  P. Lichter,et al.  Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis. , 2003, Anticancer research.

[16]  H Buerger,et al.  Demystified … Tissue microarray technology , 2003, Molecular pathology : MP.

[17]  Axel Benner,et al.  Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. , 2003, Cancer research.

[18]  C. Moskaluk,et al.  Agarose Mold Embedding of Cultured Cells for Tissue Microarrays , 2002, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[19]  Matt van de Rijn,et al.  Tissue Microarrays Are an Effective Quality Assurance Tool for Diagnostic Immunohistochemistry , 2002, Modern Pathology.

[20]  Thomas Rüdiger,et al.  Inter‐laboratory and inter‐observer reproducibility of immunohistochemical assessment of the Ki‐67 labelling index in a large multi‐centre trial , 2002, The Journal of pathology.

[21]  C Blake Gilks,et al.  Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. , 2002, American journal of clinical pathology.

[22]  K. Pienta,et al.  Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis , 2002, The American journal of surgical pathology.

[23]  D. Slamon,et al.  Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. , 2001, The American journal of pathology.

[24]  Axel Hoos,et al.  Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations , 2001, Laboratory Investigation.

[25]  O. Kallioniemi,et al.  Tissue microarrays (TMAs) for high‐throughput molecular pathology research , 2001, International journal of cancer.

[26]  H. Moch,et al.  Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.

[27]  K. Pienta,et al.  E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. , 2001, Human pathology.

[28]  O. Kallioniemi,et al.  Tissue microarray technology for high-throughput molecular profiling of cancer. , 2001, Human molecular genetics.

[29]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[30]  O. Kallioniemi,et al.  Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. , 2000, Cancer research.

[31]  Y. Chen,et al.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. , 2000, Journal of the National Cancer Institute.

[32]  M. Rubin,et al.  Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. , 2000, Human pathology.

[33]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.

[34]  H. Moch,et al.  Tissue microarrays for gene amplification surveys in many different tumor types. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  T C Gasser,et al.  Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.

[36]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[37]  K. Kinzler,et al.  Serial Analysis of Gene Expression , 1995, Science.

[38]  H. Battifora.  The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[39]  J. Mühling,et al.  Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). , 2007, Oral oncology.

[40]  M. Reiss,et al.  Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. , 2003, Oncology research.

[41]  D. Bassi,et al.  Furin expression in squamous cell carcinomas of the oral cavity and other sites evaluated by tissue microarray technology. , 2002, Acta odontologica latinoamericana : AOL.

[42]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.